UCB's Global Corporate Website
Welcome to UCB in the United States

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Aug

09

Improving Diversity in Dermatology

This August, the theme for Psoriasis Action Month is ‘All of Us.’ UCB is joining the National Psoriasis Foundation to shine light on the condition’s impact on diverse populations, and celebrate the diversity and inclusivity of the psoriasis community. Read more from Rhonda Peebles, Head of U.S. Dermatology, as she shares her thoughts on racial inequities in dermatology and the steps UCB is taking to move the equity needle forward. 

Aug

07

New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

Aug

05

“All of Us” vs. Psoriasis

As part of Psoriasis Action Month, Camille Lee, Head of U.S. Immunology at UCB, shares how UCB is helping find and bridge gaps in psoriatic disease care.